

Biotechnologies of Longevity: Reprogramming Cellular Time Through Regenerative and Gene-Based Interventions

Ndenga Lumbu Barack

Independent Researcher

Corresponding author

Ndenga Lumbu Barack (alias BarackEinstein97) Independent Researcher, Kinshasa, Democratic Republic of the Congo.

Received: March 06, 2026; Accepted: March 13, 2026; Published: March 23, 2026

ABSTRACT

The pursuit of longevity has transitioned from speculative ambition to a rapidly advancing scientific field driven by breakthroughs in regenerative biology, gene therapy, and cellular reprogramming. In this article, I argue that emerging longevity biotechnologies converge on a common, higher-order

Objective: the reprogramming of cellular time. I contend that strategies such as partial cellular reprogramming, gene-based interventions, senolytic clearance, and directed regeneration operate not merely to repair damage, but to actively reshape the temporal state of cells by restoring lost biological information and functional coordination. By integrating evidence from experimental and translational studies, I propose a unified framework in which longevity interventions are understood as tools to modulate biological time, rather than simply extend chronological lifespan. This perspective provides a conceptual bridge between the mechanistic understanding of aging and the applied ambition of applied biotechnology.

Keywords: Longevity Biotechnologies, Cellular Reprogramming, Biological Time, Senolytics, Regenerative Medicine, Epigenetic Rejuvenation, Gene Therapy, Cellular Senescence, Tissue Engineering, Temporal Engineering, Health Span, Aging Interventions, Gero Science, Precision Medicine, Systems Medicine

Introduction

For decades, the dominant biological narrative cast aging as an irreversible, unidirectional decline—a passive accumulation of damage leading to inevitable functional loss. Recent biotechnological advances have dismantled this fatalistic view, revealing that key features of aging are plastic, malleable, and subject to reprogramming.

In this article, I explore how the vanguard of longevity science—partial reprogramming, gene therapy, senolytics, and directed regeneration—collectively reframe aging not as a fixed endpoint, but as a modifiable temporal state. These technologies allow us to intervene not just in time, but upon the biological timeline itself, offering the unprecedented possibility to reset, slow, or redirect the trajectory of cellular aging.




Figure 1: Paradigm Shift: From Linear Decline to Programmable Cellular Time

A dual-timeline diagram. Top Timeline (Old Paradigm): A single, straight arrow sloping downward from "Youth" to "Aged," labeled "Irreversible Functional Decline," with icons of accumulating damage (**DNA breaks, protein aggregates**). Bottom Timeline (**New Paradigm**): A dynamic, multi-directional line starting at "Youthful State." It shows interventions (**arrows**) that can "Reset" the timeline (**via Reprogramming**), "Slow" its

slope (via **Gene Therapy**), "Remove Blocks" (via **Senolytics**), and "Rebuild" its trajectory (via **Regeneration**), leading to an extended "Health span." Created with BioRender.com.

Cellular Time

The Modifiable Substrate of Aging

Biological time is distinct from the tick of a clock. It is an internal, dynamic state of a cell or organism, encoded in:

- its epigenetic landscape,
- its transcriptional and metabolic rhythms,
- its regenerative and repair capacity.

Aging, I argue, is the progressive desynchronization and informational decay of this internal clock. Longevity biotechnologies, therefore, target this substrate: they are instruments for reprogramming cellular time, moving the system from a state of aged dysregulation back toward one of youthful coherence.

Partial Cellular Reprogramming

Resetting the Epigenetic Clock from Pluripotency to Rejuvenation

The revolutionary discovery of cellular reprogramming via Yamanaka factors (Oct4, Sox2, Klf4, c-Myc) proved cellular identity is fluid. A more nuanced application—partial or transient reprogramming—has since emerged as a powerful longevity strategy. By briefly exposing aged cells to these factors, we can induce rejuvenation without erasing cellular identity [1,2].

Reprogramming as Temporal Reversal

I interpret this phenomenon not as simple dedifferentiation, but as epigenetic time travel. The cell's core identity remains, while the accumulated noise and dysregulation of age are stripped away. This demonstrates conclusively that a significant portion of the aged cellular state is a reversible software error, not irreversible hardware damage.

Gene-Based Therapies

Editing the Trajectory of Time Beyond Monogenic Disease: Targeting the Aging Phenotype

While gene therapy historically targeted single-gene disorders, its new frontier is the polygenic, systemic process of aging. Interventions now aim at master regulatory pathways:

- Telomere maintenance (e.g., TERT activation),
- Stress resistance and homeostasis (e.g., FOXO, SIRT pathways),
- Enhanced DNA repair and protectors.

Editing the Slope of the Curve

From a temporal perspective, these therapies do not cure aging; they alter its calculus. By bolstering maintenance and defense systems, they effectively reduce the rate of informational entropy, flattening the downward slope of functional decline and preserving the system in a more youthful state for longer.

Senolytics

Removing Temporal Logjams

Senescence as a Pathological Time-Lock

Senescent cells are not just dormant; they are biologically arrested in a detrimental state, secreting inflammatory signals that poison their microenvironment and disrupt tissue coordination. Their

accumulation is less like wear and tear and more like a systemic traffic jam that grinds tissue function to a halt.

Clearance to Restore Flow

Senolytic compounds that selectively eliminate these cells [3], act as temporal uncloggers. By removing this pathological bottleneck, they restore the dynamic flow of tissue repair, regeneration, and communication, allowing the biological system to resume more youthful patterns of function.

Directed Regeneration

Engineering Youthful Tissue Architecture

True regeneration is not mere cell division; it is the orchestrated recapitulation of developmental programs to rebuild functional structure. Advances in stem cell biology and tissue engineering now allow us to guide this process—to deliver cells, scaffolds, and signals that instruct tissues to reconstruct their youthful form and function.

This approach directly counters the age-related decline in regenerative capacity, actively rebuilding the biological landscape as opposed to merely slowing its decay.

A Unified Framework

The Temporal Engineering Toolkit

Despite their mechanistic diversity, these four pillars converge on a unified principle: they are all modalities for reprogramming biological time.

- Reprogramming resets epigenetic time.
- Gene Therapy alters the slope of time's trajectory.
- Senolytics removes blocks that distort time's flow.
- Regeneration rebuilds structures that exist in youthful time.
- Together, they form an integrated toolkit for temporal engineering, allowing us to intervene at different points in the process of aging's desynchronization.




Figure 2: The Unified Temporal Engineering Toolkit for Longevity.

A central graphic of a stylized "Cellular Clock" with manipulable gears. Four colored tools (icons) interact with it:

- 1) A "Rewind" symbol (blue) acting on the clock's epigenetic face (Reprogramming).
- 2) A "Speed Dial" (green) adjusting the clock's hands (Gene Therapy).
- 3) A "Clearing Tool" (orange) removing "senescent cell" debris clogging the gears (Senolytics).
- 4) A "Blueprint & Hammer" (purple) rebuilding the clock's

structure (Regeneration). Together, they demonstrate complementary approaches to modulating a single target: biological time. Created with BioRender.com.

Implications

From Reactive Repair to Proactive Temporal Design

This unified framework transforms how we envision longevity medicine. It suggests:

- **Sequenced Therapeutic Strategies:** Interventions can be

logically ordered (e.g., clear senescence before inducing regeneration).

- **Personalization via Biological Age:** Therapies can be tailored to an individual's specific temporal state, not just their disease.
- **Aging as a Treatable Variable:** Aging transitions from an immutable fact of life to the primary, modifiable risk factor for chronic disease.




Figure 3: From Paradigm to Practice: Strategic Sequencing of Temporal Interventions.

A clinical decision flowchart. It starts with "Patient Biological Age & State Assessment" (inputs: epigenetic clock, senescence burden, tissue integrity). Based on the profile, the chart recommends a logical sequence: e.g., "High Senescence Burden" → First-line: Senolytic Therapy; Followed by: Pro-regenerative signals. Alternatively, "Epigenetic Aging" → First-line: Partial Reprogramming; Supported by: Gene Therapy for stability. This visualizes the move from one-size-fits-all to personalized, time-targeted therapeutic design. Created with BioRender.com [4-117].

Conclusion

I propose that the defining quest of 21st-century longevity science is not to combat aging's symptoms piecemeal, but to gain mastery over the temporal architecture of life itself. By reframing aging as a malleable state of biological time, we unlock a new paradigm. In this paradigm, technologies that restore information, clear noise, and resynchronize systems do not just

add years to life-they reprogram the very experience of those years. The goal shifts from extending lifespan to engineering health span, transforming aging from a passive descent into an active process we can guide and reshape.

References

1. Ocampo A. In vivo amelioration of age-associated hallmarks by partial reprogramming. 2016. 167: 1719-1733.
2. Lu Y. Reprogramming to recover youthful epigenetic information and restore vision. Nature, 2020. 588: 124-129.
3. Kirkland JL, Tchkonja T. Senolytic drugs: from discovery to translation. Journal of Internal Medicine. 2020. 288: 518-536.
4. López-Otín C. The hallmarks of aging. 2013. 153: 1194-1217.
5. Ndenga B, Kayumba MD, DJM. Cellular Aging as an Information–Entropy Process: Rethinking the Biological Arrow of Time (Version V1). Zenodo. 2026.

6. Ndenga B, Kayumba MD, DJM. Epigenetic Drift, Proteostasis Collapse and Mitochondrial Noise: Molecular Drivers of Biological Time (Version V1). Zenodo. 2026.
7. Bibliographical references of Ndenga Lumbu Barack
8. Chuck C, Robinson J, Ndenga B. Bio-Adaptive Quantum Error Correction: Immune-Inspired Priors Enable 22–65% Overhead Reduction in Surface-Code Decoding (Version V1). Zenodo. 2025.
9. Maman Moussa Maman M, Ndenga B. Nutritional and Nutraceutical Valorization of Edible Grasshoppers from Niger: A Multi-Omics Characterization Integrated with Artificial Intelligence for Personalized Food Formulations (Version V1). Zenodo. 2025.
10. Maman Moussa Maman M, Ndenga B, SORE I. Mechanisms of Action and Therapeutic Synergies Between Nutrition, Physical Activity, and Phytotherapy for Cardiometabolic Prevention: A Narrative Review and Integrative Framework for the African Context (Version V1). Zenodo. 2026.
11. Maman Moussa Maman M, Ndenga B. Mathematical and Nutritional Modeling for Predicting the Effectiveness of Malaria Preventive Interventions: An Integrated Epidemiological Framework for Population-Level Risk and Response Optimization (Version V1). Zenodo. 2025.
12. Maman Moussa Maman M, Ndenga B. Beyond Body Mass Index: Development of the Adjusted Central Corpulence Index (ICCA) Integrating Age, Sex, and Abdominal Adiposity for Cardiometabolic Risk Assessment (Version V1). Zenodo. 2025.
13. Maman Moussa Maman M, Ndenga B, SORE I, Makiasi hambadiana Y, Schouna Meni C. Integrative Modulation of Telomeric Dynamics and Cellular Senescence through Nutrition, Phyto-Pharmacological Compounds, Translational Medicine, Artificial Intelligence, and Quantum Simulation. (Version V1). Zenodo. 2025.
14. Maman Moussa Maman M, Ndenga B, SORE I, Makiasi hambadiana Y, Schouna Meni C. Complementary Mechanisms of Action and Potential Synergies Between Nutrition, Physical Activity, and Phytotherapy in Cardiometabolic Prevention: A Narrative Review and Theoretical Framework for the African Context (Version V1). Zenodo. 2026.
15. Maman Moussa Maman M, Ndenga B, SORE I, Makiasi hambadiana Y, Schouna Meni C. Development and Validation of ICCA-O (Optimized Adjusted Central Adiposity Index): A Composite Cardio-Metabolic Risk Indicator Integrating BMI, WHR, WtHR, ABSI, and BAI (Version V1). Zenodo. 2026.
16. Maman Moussa Maman M, Ndenga B. Artificial Intelligence-Driven Personalized Optimization of Antimalarial Therapies Through the Integration of Nutrition, Phytotherapy, and Pharmacology: A Multi-Factor Predictive Modeling Framework (Version V1). Zenodo. 2025.
17. Maman Moussa Maman M, Ndenga B. AI-Enhanced Biochemical Discovery and Optimization of Antimalarial Compounds from Indigenous Medicinal Plants: An Integrative Framework for Data-Driven Natural Product Drug Development (Version V1). Zenodo. 2025.
18. Makiasi Hambadiana Y, Ndenga B. Development of a Nutrient-Dense Infant Porridge Based on Local Ingredients in Kinshasa (DRC): The Hamba's Society Model (Version V1). Zenodo. 2025.
19. Makiasi Hambadiana Y, Ndenga B. Prostate-Protective Bioactivity of Cucurbita maxima Seeds: Molecular Pathways, Endocrine Regulation, and Clinical Relevance (Version V1). Zenodo. 2025.
20. Makiasi hambadiana Y, Ndenga B. Biocatalytic and Cytoprotective Role of the Zinc–L–Carnosine Complex in Gastric Mucosal Regeneration (Version V1). Zenodo. 2025.
21. Makiasi Hambadiana Y, Ndenga B. Functional and Preventive Potential of Cucurbita maxima as a Nutritional Therapeutic Agent. (Version V1). Zenodo. 2025.
22. Ndenga B, Kayumba MD DJM. Cellular Aging as an Information–Entropy Process: Rethinking the Biological Arrow of Time (Version V1). Zenodo. 2026.
23. Ndenga B. Information-Driven Order Formation in Natural and Artificial Systems (Version V1). Zenodo. 2025.
24. Ndenga B. Immuno-Engineering of Hematopoietic Stem Cells for Durable Immune Resistance to HIV: From the CCR5 Δ 32 Mutation to Autologous Gene Therapies Mediated by Lentiviral Vectors (Version V1). Zenodo. 2026.
25. Ndenga B, Kayumba MD DJM. Epigenetic Drift, Proteostasis Collapse and Mitochondrial Noise: Molecular Drivers of Biological Time (Version V1). Zenodo. 2026.
26. Ndenga B. Beyond HIV: Immuno-Engineering as a New Therapeutic Paradigm for Chronic Infectious and Oncological Diseases — Scientific Legacy and Translational Perspectives (Version V1). Zenodo. 2026.
27. Ndenga B. Combinatorial Therapeutic Strategies and Multi-Modal Synergies for Functional HIV Remission: Modeling and Optimization of Integrated Therapeutic Sequences (Version V1). Zenodo. 2026.
28. Ndenga B. Reading and Transcription of a Tetra-Stranded Genetic Polymer: Decoding Channels, Controlled Ambiguities, and the Formal Definition of the Q-Code (Version V1). Zenodo. 2025.
29. Ndenga B. Translational, Bioethical, and Global Equity Challenges in the Deployment of Anti-HIV Biotherapies: From the Research Laboratory to the Most Affected Populations (Version V1). Zenodo. 2026.
30. Ndenga B. Next-Generation CAR-T Cells for HIV Cure Strategies: Dual-Specific Chimeric Antigen Receptors for Targeted Elimination of Latent Reservoirs Toward Artificial, Durable, and Adaptive Immune Surveillance (Version V1). Zenodo. 2026.
31. Ndenga B. Information-Theoretic Capacity of a Tetra-Stranded Hereditary Polymer: Effective Alphabets, Encoding Density, and Readout Constraints in Q-DNA (Version V1). Zenodo. 2025.
32. Ndenga B. Replication of a Tetra-Stranded Genome: Mechanistic Scenarios and Minimal Enzymatic Constraints for Q-DNA (Version V1). Zenodo. 2025.
33. Ndenga B. Catalogue of Tetra-Stranded Helical Architectures: Classes, Topological Invariants, and Structural Transitions (Version V1). Zenodo. 2025.
34. Ndenga B. Q \leftrightarrow D Kinetics: Nucleation, Propagation, and Kinetic Traps in a Tetra-Stranded Hereditary Polymer (Version V1). Zenodo. 2025.
35. Ndenga B. Programmable Nanomedicine and Multifunctional Vectors for the Selective Targeting of HIV-1 Reservoirs: Toward a Next-Generation Shock & Kill Strategy (Version V1). Zenodo. 2026.

36. Ndenga B. Thermodynamics of a Tetra-Stranded Genome: Stability, Thresholds, and Entropic Constraints (Version V1). Zenodo. 2025.
37. Ndenga B. Q-DNA: A Formal Definition of a Canonical Tetra-Stranded Hereditary Polymer Beyond the Double Helix (Version V1). Zenodo. 2025.
38. Ndenga B. Quantum π in Biomolecular Dynamics: Proteins as Nano-Quantum Fluids (Version V1). Zenodo. 2025.
39. Ndenga B. Evolvability and Selection in a Tetra-Stranded Genome: Robustness, Modularity, and Adaptive Dynamics in Q-DNA (Version V1). Zenodo. 2025.
40. Ndenga B, Sharma H. Information Against Entropy: Toward a Governing Principle of Organization in Complex Systems (Version V1). Zenodo. 2025.
41. Ndenga B, Himanshi, sharma. Microcapsule-Enabled Self-Healing Silicon Anodes for Next-Generation Lithium-Ion Batteries: A Conceptual Design, Materials Framework, and Technical Feasibility Study (Version V1). Zenodo. 2025.
42. Ndenga B. Rigidity, Torsion, and Mechanical Response of a Tetra-Stranded Genome: A Unified Theoretical and Experimental Framework for Q-DNA Elasticity (Version V1). Zenodo. 2025.
43. Ndenga B. Mutation Landscape and Error Correction in Q-DNA: Correlated Errors, Structural Redundancy, and Topological Self-Correction in a Tetra-Stranded Hereditary Polymer (Version V1). Zenodo. 2025.
44. Ndenga B. Legume-Derived Anti-Angiogenic Networks Targeting Renal Cell Carcinoma: Mechanistic Insights into Polyphenol-Saponin-Fiber Bioactive Complexes from *Phaseolus vulgaris* (Version V1). Zenodo. 2025.
45. Ndenga B. Climate-Adaptive Batteries: Passive Thermal Regulation of Lithium-Ion Batteries Using Thermochromic Functional Surface Films (Version V1). Zenodo. 2025.
46. Ndenga B. Atomistic Stability of Q-DNA: Molecular Dynamics Simulations and Structural Persistence Criteria (Version V1). Zenodo. 2025.
47. Ndenga B. Four-Strand Pairing Beyond Watson-Crick: Interaction Hypergraphs, Controlled Degeneracy, and Sequence Constraints (Version V1). Zenodo. 2025.
48. Ndenga B. Information, Entropy, and System Dynamics: A Unified Framework Toward an Extended Thermodynamic Principle of Organization Across Physical, Biological, and Computational Systems (Version V1). Zenodo. 2025.
49. Ndenga B. The Informational Foundations of Organization in Physical and Biological Systems: Toward an Extended Thermodynamic Principle of Self-Organization (Version V1). Zenodo. 2025.
50. Ndenga B. On Organizational Efficiency and the Limits of Non-Equilibrium Thermodynamics Toward an Information-Centered Theory of Organization (Version V1). Zenodo. 2025.
51. Ndenga B. R-Law AI: A Thermodynamic Information-Entropy Framework for Self-Organizing Neural Networks Based on the IOE Principle (Version V1). Zenodo. 2025.
52. Ndenga B. The Extended Fifth Law of Thermodynamics: Establishing Information as a Fundamental Physical Quantity (Version V1). Zenodo. 2025.
53. Ndenga B. The principle of informed organizational efficiency: A Comprehensive Foundational Framework for an Extended Fifth Law of Thermodynamics (Version V1). Zenodo. 2025.
54. Ndenga B. Nano-Turbulence in Biological Systems: A New Paradigm (Version V1). Zenodo. 2025.
55. Ndenga B. Schrödinger-Navier-Stokes- π Unified Computational Framework: A Unified Theoretical and Numerical Architecture for Quantum-Coherent Fluid Dynamics Across Physical and Biological Scales (Version V1). Zenodo. 2025.
56. Ndenga B. The Complete Solution to the Glass Transition: A Unified Energy-Topology Landscape (ETL) Framework (Version V1). Zenodo. 2025.
57. Ndenga B. Quantum-Fluid Interpretation of Enzymatic Tunnels and Energy Transport (Version V1). Zenodo. 2025.
58. Ndenga B. Schrödinger-Navier-Stokes-Quantum- π : A Unified Model and Hybrid Numerical Method for Quantum Fluids with π -Phase Structure (Version V1). Zenodo. 2025.
59. Ndenga B. Quantum π -Unification II: Definition, Mathematical Structure, and Foundational Properties of the Quantum π for Molecular Systems (Version V1). Zenodo. 2025.
60. Ndenga B. Electrostatics of a Tetra-Stranded Polymer: Ionic Condensation and Nonlinear Screening (Version V1). Zenodo. 2025.
61. Ndenga B. H-ImmQ π Decoder v2.0: A Bio-Inspired Quantum Error Decoder Integrating Immune Adaptation, Quantum- π Phase Control, and Quantum Metabolism (Version V1). Zenodo. 2025.
62. Ndenga B. The Octet Rule Revisited: A Quantum-Continuum Framework for Chemical Bonding (Version V1). Zenodo. 2025.
63. Ndenga B. Foundations of Quantum- π in Molecular Systems: A Fundamental Descriptor of Delocalization, Electronic Structure, and Molecular Stability. Zenodo. 2025.
64. Ndenga B. Quantum π -Index in Advanced Materials: Predictive Framework for Nanostructures, Functional Polymers, and Superconducting States (Version V1). Zenodo. 2025.
65. Ndenga B. Crystal-Guided AI Phototherapy for Personalized Oncology (Version V1). Zenodo. 2025.
66. Ndenga B. Quantum π -Driven Predictive Chemistry: Applications to Reactivity, Electronic Structure, and Simulation-Based Forecasting (Version V1). Zenodo. 2025.
67. Ndenga B. Numerical Solution of the Navier-Stokes Equations in 3D Using the Finite Volume Method: Application to the Millennium Problem. Zenodo. 2025.
68. Ndenga B. Electronless Nuclear Matter: Magnetic Confinement and Bonding of Bare Nuclei in Extreme Fields (Version V1). Zenodo. 2025.
69. Ndenga B, Ndenga B. AutoEvoChem V2.0 – A Smart Molecular Simulation & Synergy AI Toolkit for Computational Chemists and Biopharma Researchers. Zenodo. 2025.
70. Ndenga B. NanoChemicalDisc RDC-1000: A Novel Molecular Approach to Low-Cost Data Storage Using Colorimetric Encoding. Zenodo. 2025.
71. Ndenga B. Autoevolving Nanodisk with Unlimited Memory: A Bioinspired and Quantum-Spiritual Approach (Version V1). Zenodo. 2025.
72. Ndenga B. Self-Adaptive Photosynthetic Quantum Crystal: A Bioinspired Innovation for Intelligent Light Harvesting and Energy Conversion (Version V1). Zenodo. 2025.

73. Ndenga B. Quantum-Nuclear DNA Computing: Using Nucleotide Spin States as Biological Quantum Bits for Molecular Calculations (Version V1). Zenodo. 2025.
74. Ndenga B. BECChem: Self-Evolving Chemical AI for Advanced Molecular Analysis (Version V1). Zenodo. 2025.
75. Ndenga B. Nuclear Matter Without Electrons: The Magneto-Nuclear Periodic Table (MNPT) and the Taxonomy of Nucleomorphs (Version V1). Zenodo. 2025.
76. Ndenga B. Design of Multi-Target Hybrid Molecules for Synergistic Therapy of Malaria and Human African Trypanosomiasis (Version V1). Zenodo. 2025.
77. Ndenga B. Biological Neural Calculator Using Plant-Based Electromagnetic Responses (Version V1). Zenodo. 2025.
78. Ndenga B. Title: Molecular Wormhole Chemistry: Electronic Non-Locality Induced by Wormhole-Like Geometries in Conjugated Molecular Systems (Version V1). Zenodo. 2025.
79. Ndenga B. Towards a Unified AI-Driven Quantum Framework: Beyond Density Functional Theory for 3D Materials. 2025.
80. Ndenga B. A Knot-Theoretic Approach to Turbulence: Toward Predictive Invariants in 3D Fluid Flows (Version V1). Zenodo. 2025.
81. Ndenga B. Towards a Unified Field Theory of Chemistry: Bridging Quantum, Organic, and Biochemical Reactions through a Single Formalism (Version V1). Zenodo. 2025.
82. Ndenga B. Vacuum Metabolism: A Theoretical Framework for Biological Exploitation of Quantum Zero-Point Energy (Version V1). Zenodo. 2025.
83. Ndenga B. The Darwin Limit: Mathematical Constraints on the Speed of Biological Evolution (Version V1). Zenodo. 2025.
84. Ndenga B. Integrating AI, Photonics, and Molecular Modeling: The Future of Precision Medicine (Version V1). Zenodo. 2025.
85. Ndenga B. Photonics + AI: Revolutionizing in Silico Drug Design (Version V1). Zenodo. 2025.
86. Ndenga B. Photonics and AI in Computational Oncology: Accelerating the Design of Next-Generation Cancer Therapies (Version V1). Zenodo. 2025.
87. Ndenga B. AI-Driven Light-Spectrum Optimization for Photonic Drug Discovery (Version V1). Zenodo. 2025.
88. Ndenga B. Photon-Enhanced AI Platforms for Multimodal Therapeutics (Version V1). Zenodo. 2025.
89. Ndenga B. AI-Optimized Photon-Assisted Molecular Docking for Rapid Drug Discovery (Version V1). Zenodo. 2025.
90. Ndenga B. Photonics + AI for Real-Time Molecular Interaction Mapping (Version V1). Zenodo. 2025.
91. Ndenga B. Light-Speed AI for Personalized Drug Optimization (Version V1). Zenodo. 2025.
92. Ndenga B. Introduction to the Concept of π in the Quantum World (Version V1). Zenodo. 2025.
93. Ndenga B. π in Fundamental Quantum Systems (Version V1). Zenodo. 2025.
94. Ndenga B. Spectrally-Driven Active Learning Enables Femtojoule-Efficient Discovery of Photocatalysts in Under One Hour: The LuminaFemto AI Platform (Version V1). Zenodo. 2025.
95. Ndenga B, Ometie C. Polyunsaturated Neuroprotectants as Adjuvant Agents: Anti-Proliferative and Membrane-Stabilizing Effects of Nuciferous Compounds from Juglans regia in Invasive Glioma Models (Version V1). Zenodo. 2025.
96. Ndenga B. The IOE Ratio: Quantifying Organizational Potential in Complex Systems (Version V1). Zenodo. 2025.
97. Ndenga B. Bio-IA Supercomputer: Concept, Design, and Implementation of an AI-Integrated Biocomputer (Version V1). Zenodo. 2025.
98. Ndenga B. π and the Quantum Structure of Probability: From Wavefunction Normalization to Statistical Distributions (Version V1). Zenodo. 2025.
99. Ndenga B. π as a Quantum Signature: Applications and Universal Implications (Version V1). Zenodo. 2025.
100. Ndenga B. Hormonal Receptor Modulation by Lipid Phytoconstituents: The Role of Monounsaturated Fatty Acids and Folate Derivatives from *Persea americana* in Endometrial Carcinogenesis Prevention (Version V1). Zenodo. 2025.
101. Ndenga B. Gastro-Oncology of Ginger: A Molecular Dissection of Gingerols and Shogaols as Dual Anti-Inflammatory and Anti-Mutagenic Agents in Gastric Carcinogenesis-with AutoEvoChem V2.0 Simulation Pipeline (Version V1). Zenodo. 2025.
102. Ndenga B. Advanced Structural Vaccinology and Mosaic Nanoparticles for the Rational Induction of Broadly Neutralizing Antibodies Against HIV: Circumventing the Extreme Hypervariability of the Viral Envelope (Version V1). Zenodo. 2026.
103. Ndenga B. π and Delocalized Electrons: A Quantum-Chemical Reassessment of Coherence, Stability, and Molecular Structure (Version V1). Zenodo. 2025.
104. Ndenga B. Toward a Quantum Definition of π in Molecular Systems: Original Formula, Mathematical Framework, and Foundational Implications (Version V1). Zenodo. 2025.
105. Ndenga B. Innovative Limonoid-Based Targeted Therapy: Citrus-Derived Compounds for Selective Apoptosis and Cell-Cycle Control in Estrogen-Dependent Breast Cancer (Version V1). Zenodo. 2025.
106. Ndenga B. The HIV Paradox: Acquired Immunodeficiency, Latent Reservoirs, and Mechanisms of Viral Persistence Why Antiretroviral Therapies Fail to Achieve a Curative Outcome (Version V1). Zenodo. 2026.
107. Ndenga B. Carotenoid Signaling and Mitochondrial Protection at the Crossroads of Cardio-Oncology: Lycopene as a Dual Modulator of Cardiovascular and Cancer Risk (Version V1). Zenodo. 2025.
108. Ndenga B. Resolving Nanoscale Reaction Kinetics: A Unified Framework from Classical Chemistry to Quantum Collectivity (Version V1). Zenodo. 2025.
109. Ndenga B. Q-BattX Cloud™: A Quantum-AI-Driven Cloud Platform for Next-Generation Energy Storage Simulation and Optimization (Version V1). Zenodo. 2025.
110. Ndenga B. Correlated Quantum Matter Beyond Band Theory: A Continuum-Interaction Formalism for Strongly Coupled Electrons (Version V1). Zenodo. 2025.
111. MULONSO H, Ndenga B, MATAMBA MPINGIJA C. Techniques Used for Analyzing Fatty Acids in Food (Version V1). Zenodo. 2025.
112. MULONSO H, Ndenga B, Kabena Ilunga M. Antioxidant Potential of *Cymbopogon citratus* Leaf Extracts in the

- Prevention of Oxidative Stress Involved in Cancer (Version V1). Zenodo. 2025.
113. MULONSO H, Ndenga B, MATAMBA MPINGIJA C. Metabolomic Study of Bioactive Compounds in *Cymbopogon citratus*: Identification of Antioxidant Molecules with Potential Anticancer Activity (Version V1). Zenodo. 2025.
114. MULONSO H, Ndenga B. Phytochemical Analysis and Free Radical Scavenging Activity of Methanolic and Chloroformic Extracts of *Cymbopogon citratus*: Implications for Cancer Chemoprevention (Version V1). Zenodo. 2025.
115. MULONSO H, Ndenga B. Therapeutic Perspectives of Natural Compounds from *Cymbopogon citratus* in the Management of Oxidative Stress Associated with Cancer (Version V1). Zenodo. 2025.
116. MULONSO H, Ndenga B. Evaluation of the Anti-inflammatory and Antioxidant Effects of *Cymbopogon citratus* as Adjuvant Agents in Cancer Therapy (Version V1). Zenodo. 2025.
117. MULONSO H, Ndenga B. Contribution of Enzymatic and Non-Enzymatic Antioxidants from *Cymbopogon citratus* to Cellular Protection Against Oxidative Damage in Cancer (Version V1). Zenodo. 2025.